---
title: Beyond Antifungal MICs 
subtitle: <br> *Fungicidal activity, biofilms and tissue distribution*
author: <br> Russell E. Lewis, Pharm.D. <br> Associate Professor- Infectious Diseases <br> Department of Medical and Surgical Sciences <br> University of Bologna
format:
  revealjs: 
    smaller: true
    scrollable: true
    theme: default
    fig-cap-location: top
    incremental: true 
    slide-number: false
    chalkboard: 
      buttons: true
    preview-links: auto
    css: styles.css
bibliography: references.bib
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Agenda

::: columns
::: {.column width="50%"}
-   How do deep-seated infections and biofilms alter drug penetration and fungal killing?
-   How can we adapt antifungal selection an dosing strategies to account for these changes?
:::

::: {.column width="50%"}
![](images/candida_tissue.png){fig-align="center" width="350"}
:::
:::

## deep-seated, *adj*

<br>

<br>

"Being so far below the surface as to be non-susceptible to superficial examination, study or treatment" [^1]

<br>

"...very fixed and strong; difficult to change or destroy." [^2]

------------------------------------------------------------------------

### Deep-seated vs. "uncomplicated" infections

::: columns
::: {.column width="50%"}
![](images/deep_sites.png){fig-align="center" width="600"}
:::

::: {.column width="50%"}
![](images/catheter.png){fig-align="center"}
:::
:::

## PK/PD of Antifungal Therapy

![](images/pkpd.png)

<font size ="4"> [@theuretzbacher2012] </font>

## How important is fungicidal activity?

<br>

| Disease                 | Evidence                                                                                                                                    | References                                           |
|---------------|------------------------------------------|---------------|
| Cryptococcal meningitis | Early fungicidal activity (EFA) \> 0.2 log~10~/day in CSF is a surrogate marker for 18 week all-cause mortality                             | [@bicanic2009; @pullen2020; @rhein2016; @jarvis2022] |
| Invasive candidiasis    | Fungicidal therapy (AMB or echinocandin) is associated with a higher probability of early therapeutic success and decreased risk of relapse | [@kumar2018; @andes2012]                             |
| Invasive aspergillosis  | Poorer outcomes reported with fungistatic echinocandin monotherapy in EORTC probable/proven aspergillosis                                   | [@ullmann2018; @viscoli2009]                         |

## Biofilm-mediated resistance

![](images/biofilm_resistance.png){fig-align="center" width="1600"}

<font size ="4"> [@ciofu2022;@mitchell2015] </font>

## How do fungal cells survival fungicidal drug exposure?

::: columns
::: {.column width="50%"}
![](images/deep_sites.png){fig-align="center" width="600"}
:::

::: {.column width="50%"}
![](images/catheter.png){fig-align="center"}
:::
:::

## Conclusions {.smaller}

## Acknowledgements

<br>

All figures, unless otherwise cited, were created at: [www.biorender.com](www.biorender.com)

## References

[^1]: *Oxford English Dictionary* 2021

[^2]: Merriam-Webster.com
